Brexanolone in Postpartum Depression: Post Hoc Analyses to Help Inform Clinical Decision-Making

Background: Brexanolone (BRX) injection was approved by the United States Food and Drug Administration in 2019 for the treatment of adults with postpartum depression (PPD) based on two Phase 3 clinical trials. Materials and Methods: Data from the three trials were combined. PPD-specific 17-item Hami...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerbasi, Margaret E., Meltzer-Brody, Samantha, Acaster, Sarah, Fridman, Moshe, Bonthapally, Vijayveer, Hodgkins, Paul, Kanes, Stephen J., Eldar-Lissai, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957380/
https://www.ncbi.nlm.nih.gov/pubmed/33181049
http://dx.doi.org/10.1089/jwh.2020.8483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957380/
https://www.ncbi.nlm.nih.gov/pubmed/33181049
http://dx.doi.org/10.1089/jwh.2020.8483

Ejemplares similares